ImmunityBio, Inc. vs Abbvie Inc.
IBRX vs ABBV — side-by-side comparison from reported financials. IBRX leads 2, ABBV leads 6 of 8 comparable metrics.
ImmunityBio, Inc.
IBRX · Healthcare
$10.57+6.66%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | IBRX | ABBV |
|---|---|---|
| Price | $10.57 | $276.43 |
| Market cap | $11.2B | $488B |
| Revenue (TTM) | $166M | $64.4B |
| Revenue growth | +678.6% | +1.8% |
| Net margin | -598.6% | 9.8% |
| Free cash flow | -$288M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +333.2% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | — | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -193% | 96% |
| Altman Z-score | -6.14 | 2.33 |
| CV checks passed | 4 of 9 | 9 of 9 |
| Employees | 691 | 57,000 |
Full résumé-style profiles: IBRX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.